Current status of biosimilars in the treatment of inflammatory bowel diseases.
- Author:
Dong Il PARK
1
Author Information
- Publication Type:Review
- Keywords: Inflammatory bowel diseases; Biosimilar; Pharmacy; CT-P13
- MeSH: Biological Therapy; Colitis, Ulcerative; Crohn Disease; Delivery of Health Care; Health Care Costs; Humans; Illinois; Incheon; Infliximab; Inflammatory Bowel Diseases*; Korea; Lakes; Pharmacy; Prospective Studies; Retrospective Studies; Rheumatic Diseases; Trees
- From:Intestinal Research 2016;14(1):15-20
- CountryRepublic of Korea
- Language:English
- Abstract: Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.
